glp 1 and liver disease SGLT-2 inhibitors GLP-1 receptor agonists in metabolic dysfunction-associated fatty Glucagon-like peptide (GLP)-1 and GLP-2
Description
Clinical trial data suggest that gastrointestinal side effects, including any reflux symptoms, typically improve over time as patients develop tolerance to the medication
10.1016/j.cmpb.2025.108658 Comput Methods Programs Biomed
For patients who want metabolic benefits without significant weight loss, Sinclair recommends doctor-supervised microdosing
For women who havent responded well to metformin alone, adding a GLP-1 receptor agonist can be a game-changer
PMCID: PMC11034947
